Quality of life improves significantly after real-world oral immunotherapy for children with peanut allergy
Peanut oral immunotherapy (POIT) is a novel and active form of treatment for patients with peanut allergy, with multiple research studies supporting its efficacy and safety. However, there are limited data available on changes in patients' quality of life (QoL) after successful desensitization. The Food and Drug Administration in the United States recently approved the first POIT drug for commercial use.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Andrea C. Blackman, Kristen A. Staggers, Lauren Kronisch, Carla M. Davis, Aikaterini Anagnostou Source Type: research
More News: Allergy | Allergy & Immunology | Asthma | Children | Food and Drug Administration (FDA) | Immunotherapy | Peanuts | Study | USA Health